ストックスクリーナーアプリを入手
11.68
1.35%
-0.16
前日終値:
$11.84
開ける：
$11.88
24時間の取引高:
62,728
Relative Volume:
0.67
時価総額：
$3.54B
収益：
$306.77M
当期純損益:
$-618.38M
株価収益率:
-5.9289
EPS:
-1.97
ネットキャッシュフロー:
$-343.00M
1週間 パフォーマンス:
-5.96%
1か月 パフォーマンス:
-10.70%
6か月 パフォーマンス:
-17.69%
1年 パフォーマンス:
+18.58%
1日の値動き範囲:
$11.61
$11.88
1週間の範囲:
$11.61
$12.44
52週間の値動き範囲:
$9.08
$18.00
Alvotech Stock (ALVO) Company Profile
ALVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
11.68 | 3.54B | 306.77M | -618.38M | -343.00M | -1.97 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | アップグレード | Citigroup | Sell → Neutral |
| 2023-09-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-07 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-06 | ダウングレード | Citigroup | Buy → Sell |
| 2022-07-26 | 開始されました | Citigroup | Buy |
すべてを表示
Alvotech (ALVO) 最新ニュース
Alvotech’s Eylea Biosimilar ‘Keeps In Mind’ US Patent Landscape - Citeline
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth hurdles - Investing.com
Alvotech (ALVO) Shares Gap Down to $11.94 on Nov 22 - GuruFocus.com
Alvotech’s Position In The Coming Biosimilar Gold Rush (NASDAQ:ALVO) - Seeking Alpha
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates - MSN
Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Yahoo Finance
Earnings call: Alvotech reported revenues of $128 million - Investing.com India
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - Investing.com Canada
Alvotech Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call: Alvotech reported revenues of $128 million By Investing.com - Investing.com Canada
Alvotech earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Alvotech earnings missed, revenue fell short of estimates - Investing.com India
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges By Investing.com - Investing.com Australia
Alvotech : First 9 Months Earnings and Business Update 2024 - Marketscreener.com
Alvotech Showcases Strong Financial Growth and Expansion - TipRanks
Alvotech Reports Financial Results for the First Nine Months of 2024 - The Manila Times
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges - Investing.com
EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab) - JD Supra
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times
Alvotech Attending Citi's Global Healthcare Conference on - GlobeNewswire
Alvotech to Present at Citi and Evercore Healthcare Conferences in December | ALVO Stock News - StockTitan
ADVANZ PHARMAEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi - Marketscreener.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for its biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA - Pharmaceutical Technology
Alvotech application for Simponi biosimilar accepted by EMA - MSN
Alvotech’s AVT05 Biosimilar Application Accepted by EMA - TipRanks
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - The Manila Times
European Medicines Agency Confirms Acceptance of Marketing - GlobeNewswire
Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar - JD Supra
Alvotech Petitions FDA To Deny Interchangeability For Rival Stelara Biosimilars - Citeline News & Insights
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech, Teva obtain FDA nod for new Selarsdi indication - Drug Store News
Exploring High Growth Tech Stocks In The US October 2024 - Simply Wall St
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - StockTitan
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
FDA approves Alvotech and Teva’s SELARSDI for new indications - MSN
Alvotech's SWOT analysis: biosimilar powerhouse stock faces growth hurdles - Investing.com
Teva, Alvotech get expanded FDA approval for Stelara biosimilar - MSN
Teva, Alvotech get expanded FDA approval for Stelara biosimilar (NYSE:TEVA) - Seeking Alpha
Alvotech and Teva Secure FDA Approval for SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - The Manila Times
Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional - GlobeNewswire
Alvotech (ALVO) 財務データ
収益
当期純利益
現金流量
EPS
0.83%
1.03%
大文字化:
|
ボリューム (24 時間):